uric acid has been researched along with ginsenosides in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, J; Su, H; Zhang, J; Zhang, Y | 1 |
| Akther, M; Han, JH; Jiang, J; Kang, TB; Kopalli, SR; Koppula, S; Lee, KH; Lian, ML; Quan, LH; Sun, X | 1 |
| Liu, Y; Ye, Q; Zhou, W; Zhu, H | 1 |
| Chen, XM; Lin, GX; Ma, HY; Tang, D; Wang, RS; Wang, SM; Wang, X | 1 |
1 review(s) available for uric acid and ginsenosides
| Article | Year |
|---|---|
Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence.
Topics: Animals; Antioxidants; Creatinine; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Ginsenosides; Interleukin-1; Interleukin-6; Panax; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Uric Acid | 2023 |
3 other study(ies) available for uric acid and ginsenosides
| Article | Year |
|---|---|
The Effects of Ginsenosides and Anserine on the Up-Regulation of Renal Aquaporins 1-4 in Hyperuricemic Mice.
Topics: Animals; Anserine; Aquaporins; Blood Urea Nitrogen; Creatinine; Drug Synergism; Drug Therapy, Combination; Ginsenosides; Humans; Hyperuricemia; Kidney; Male; Mice; Mice, Inbred BALB C; Up-Regulation; Uric Acid | 2019 |
Ginsenoside metabolite 20(S)-protopanaxatriol from Panax ginseng attenuates inflammation-mediated NLRP3 inflammasome activation.
Topics: Animals; Anti-Inflammatory Agents; Ginsenosides; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Macrophages, Peritoneal; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Panax; Peritonitis; Sapogenins; Shock, Septic; Uric Acid | 2020 |
Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Blood Sedimentation; Bone and Bones; C-Reactive Protein; Disease Models, Animal; Ginsenosides; Glutathione Peroxidase; Joints; Male; Malondialdehyde; Nanoparticles; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide Synthase Type II; NLR Family, Pyrin Domain-Containing 3 Protein; Rats, Sprague-Dawley; Superoxide Dismutase; Uric Acid | 2020 |